Role of tumor-derived exosomes mediated immune cell reprograming in cancer. 2024

Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Tumor-derived exosomes (TDEs), as topologies of tumor cells, not only carry biological information from the mother, but also act as messengers for cellular communication. It has been demonstrated that TDEs play a key role in inducing an immunosuppressive tumor microenvironment (TME). They can reprogram immune cells indirectly or directly by delivering inhibitory proteins, cytokines, RNA and other substances. They not only inhibit the maturation and function of dendritic cells (DCs) and natural killer (NK) cells, but also remodel M2 macrophages and inhibit T cell infiltration to promote immunosuppression and create a favorable ecological niche for tumor growth, invasion and metastasis. Based on the specificity of TDEs, targeting TDEs has become a new strategy to monitor tumor progression and enhance treatment efficacy. This paper reviews the intricate molecular mechanisms underlying the immunosuppressive effects induced by TDEs to establish a theoretical foundation for cancer therapy. Additionally, the challenges of TDEs as a novel approach to tumor treatment are discussed.

UI MeSH Term Description Entries

Related Publications

Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
January 2018, Journal of biological regulators and homeostatic agents,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
January 2019, Biochimica et biophysica acta. Reviews on cancer,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
October 2016, Vaccines,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
September 2018, Seminars in immunopathology,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
September 2022, Molecular pharmaceutics,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
March 2018, International journal of cancer,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
November 2022, Cancer letters,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
November 2021, Cells,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
January 2023, Frontiers in immunology,
Zening Liu, and Zichao Chen, and Jing Zhang, and Junqiu Liu, and Baohong Li, and Zhenyong Zhang, and Meichao Cai, and Zhen Zhang
May 2017, Oncology letters,
Copied contents to your clipboard!